Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

155.15USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$155.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
617,099
52-wk High
$178.17
52-wk Low
$113.66

Latest Key Developments (Source: Significant Developments)

Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Vertex Pharmaceuticals Inc ::CO'S NOVEL OPTOPATCH PLATFORM.PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES.STATE WILL ALSO RECEIVE ROYALTIES ON DRUG SALES.CO, VERTEX PHARMACEUTICALS WILL COLLABORATE FOR AT LEAST TWO YEARS.VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION.  Full Article

Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION.VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA.  Full Article

Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis
Tuesday, 13 Feb 2018 

Feb 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK).VERTEX PHARMA SAYS ANTICIPATE FY 2018 TOTAL CF NET PRODUCT REVENUE OF $2.65 BILLION TO $2.80 BILLION FROM KALYDECO, ORKAMBI AND SYMDEKO - SEC FILING.VERTEX PHARMACEUTICALS -REITERATING ‍COMBINED GAAP RESEARCH AND DEVELOPMENT, SALES, GENERAL, ADMINISTRATIVE EXPENSES IN 2018 TO BE IN RANGE OF $1.80 TO $1.95 BILLION.VERTEX PHARMA- ‍ REITERATING COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SALES, GENERAL, AND ADMINISTRATIVE EXPENSES WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION IN 2018​.  Full Article

Vertex Pharma Says FDA Approved SYMDEKO For Treating Underlying Cause Of Cystic Fibrosis
Tuesday, 13 Feb 2018 

Feb 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMACEUTICALS INC - FDA APPROVED SYMDEKO FOR TREATING UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER​.VERTEX PHARMACEUTICALS INC - ‍READY TO LAUNCH SYMDEKO AND WILL BEGIN SHIPPING IT TO PHARMACIES IN UNITED STATES THIS WEEK​.  Full Article

Vertex Pharmaceuticals Reports Q4 Shr of $0.39
Thursday, 1 Feb 2018 

Jan 31 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMACEUTICALS - QTRLY EARNINGS PER SHARE $0.39; QTRLY NON-GAAP EARNINGS PER SHARE $0.61; QTRLY TOTAL REVENUES $651.6 MILLION VERSUS $458.7 MILLION.VERTEX PHARMACEUTICALS INC Q4 EARNINGS PER SHARE VIEW $0.53, REVENUE VIEW $594.7 MILLION -- THOMSON REUTERS I/B/E/S.VERTEX PHARMACEUTICALS - QTRLY TOTAL CF NET PRODUCT REVENUES INCREASED 37 PERCENT TO $621.2 MILLION FROM $454 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM ORKAMBI INCREASED 32 PERCENT TO $365.4 MILLION FROM $276.9 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM KALYDECO INCREASED 44 PERCENT TO $255.8 MILLION FROM $177.1 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - EXPECTS COMBINED GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE IN 2018 WILL BE IN RANGE OF $1.80 BILLION TO $1.95 BILLION.VERTEX PHARMACEUTICALS - SEES 2018 COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION.VERTEX PHARMACEUTICALS - PLANS TO PROVIDE TOTAL CF PRODUCT REVENUE GUIDANCE FOR FY 2018 UPON ANTICIPATED FDA APPROVAL OF TEZACAFTOR/IVACAFTOR COMBINATION.VERTEX PHARMACEUTICALS - BOARD AUTHORIZED SHARE REPURCHASE PROGRAM OF UP TO $500 MILLION OF COMMON STOCK THROUGH DEC 31, 2019.VERTEX PHARMACEUTICALS - REPURCHASE PROGRAM IS EXPECTED TO BE EXECUTED OVER TWO YEARS.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS.VERTEX PHARMACEUTICALS - KALYDECO​ ‍STUDY MET PRIMARY SAFETY ENDPOINT, SHOWED IMPROVEMENTS ACROSS MULTIPLE ENDPOINTS.VERTEX PHARMACEUTICALS - ‍ARRIVAL STUDY GENERALLY WELL TOLERATED, SAFETY DATA WERE CONSISTENT WITH THOSE SEEN IN PREVIOUS PHASE 3 STUDIES OF IVACAFTOR​.VERTEX PHARMACEUTICALS INC - ‍VERTEX PLANS TO SUBMIT APPLICATIONS FOR IVACAFTOR TO FDA AND EMA IN Q1 OF 2018​.  Full Article

Vertex reports Q3 non-GAAP earnings per share $0.53
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Vertex Pharmaceuticals Inc :Vertex reports third-quarter 2017 financial results.Q3 non-GAAP earnings per share $0.53.Q3 GAAP loss per share $0.41.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says ‍third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016​.Says ‍increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance​.Vertex Pharmaceuticals Inc qtrly ‍product revenues for ORKAMBI $336 million and $213 million for KALYDECO​.Says ‍reiterated its 2017 combined GAAP and non-GAAP research and development and SG&A expense guidance​.Says ‍now expects total 2017 CF product revenues of $2.10 to $2.15 billion​.Vertex Pharmaceuticals Inc ‍increases FY ORKAMBI revenue guidance to $1.29 to $1.32 billion and KALYDECO revenue guidance to $810 to $830 million​.  Full Article

FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - Vertex Pharmaceuticals Inc :FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations.Says ‍guidance range for total CF product revenues in 2017 is now $1.87 billion to $2.1 billion​.Vertex Pharmaceuticals Inc- ‍vertex increased its guidance for 2017 Kalydeco product revenues to a range of $770 million to $800 million​.Says ‍increased its guidance for 2017 Kalydeco product revenues to a range of $770 million to $800 million​.  Full Article

Vertex interested in early stage assets consistent with CF focus
Thursday, 27 Jul 2017 

July 26 (Reuters) - Vertex Pharmaceuticals Inc :Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis.Vertex says expects to pick best regimens, doses for next generation triple combination CF treatments by early 2018.Vertex Pharmaceuticals says does not anticipate ending year at low end of its forecast range.  Full Article

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage: